A promising strategy change for the pharmaceutical Biovail

Share on linkedin
Share on twitter
Share on facebook
Share on email
Share on print

The revival of the pharmaceutical company Biovail (Tor., BVF, $ 13.07) is on track and could offer a good investment opportunity, according to some financial.

Read this French article on Les Affaires…

Post Author

Author

  • Claret

    Claret Asset Management specializes in offering portfolio management services to high net worth clients. We are completely independent and free of conflicts of interest. Claret was founded in 1996 with the objective of answering the growing needs of private investors.

Your wealth matters.

Sign up to our Newsletter for updates on when we publish new insights.